X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES BIOCON LTD VENUS REMEDIES/
BIOCON LTD
 
P/E (TTM) x -697.1 77.2 - View Chart
P/BV x 0.2 7.3 2.8% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 VENUS REMEDIES   BIOCON LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
BIOCON LTD
Mar-17
VENUS REMEDIES/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs2181,162 18.8%   
Low Rs82483 17.0%   
Sales per share (Unadj.) Rs365.6194.6 187.9%  
Earnings per share (Unadj.) Rs1.534.4 4.3%  
Cash flow per share (Unadj.) Rs37.948.3 78.6%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.1 0.0%  
Book value per share (Unadj.) Rs382.5241.9 158.1%  
Shares outstanding (eoy) m11.44200.00 5.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.44.2 9.7%   
Avg P/E ratio x101.023.9 422.5%  
P/CF ratio (eoy) x4.017.0 23.2%  
Price / Book Value ratio x0.43.4 11.5%  
Dividend payout %02.9 0.0%   
Avg Mkt Cap Rs m1,717164,440 1.0%   
No. of employees `0001.09.2 11.0%   
Total wages/salary Rs m3247,470 4.3%   
Avg. sales/employee Rs Th4,100.74,213.9 97.3%   
Avg. wages/employee Rs Th318.0809.0 39.3%   
Avg. net profit/employee Rs Th16.7745.2 2.2%   
INCOME DATA
Net Sales Rs m4,18338,911 10.7%  
Other income Rs m201,571 1.3%   
Total revenues Rs m4,20340,482 10.4%   
Gross profit Rs m8129,795 8.3%  
Depreciation Rs m4172,772 15.0%   
Interest Rs m380260 146.1%   
Profit before tax Rs m358,334 0.4%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m181,616 1.1%   
Profit after tax Rs m176,881 0.2%  
Gross profit margin %19.425.2 77.1%  
Effective tax rate %51.619.4 265.9%   
Net profit margin %0.417.7 2.3%  
BALANCE SHEET DATA
Current assets Rs m2,77140,477 6.8%   
Current liabilities Rs m1,93116,783 11.5%   
Net working cap to sales %20.160.9 33.0%  
Current ratio x1.42.4 59.5%  
Inventory Days Days12560 209.8%  
Debtors Days Days5483 64.9%  
Net fixed assets Rs m5,32845,073 11.8%   
Share capital Rs m1141,000 11.4%   
"Free" reserves Rs m4,17747,377 8.8%   
Net worth Rs m4,37648,377 9.0%   
Long term debt Rs m1,91121,082 9.1%   
Total assets Rs m8,42893,942 9.0%  
Interest coverage x1.133.1 3.3%   
Debt to equity ratio x0.40.4 100.2%  
Sales to assets ratio x0.50.4 119.8%   
Return on assets %4.77.6 61.9%  
Return on equity %0.414.2 2.7%  
Return on capital %6.612.6 52.3%  
Exports to sales %00-   
Imports to sales %20.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m858NA-   
Fx inflow Rs m012,988 0.0%   
Fx outflow Rs m8587,899 10.9%   
Net fx Rs m-8585,089 -16.9%   
CASH FLOW
From Operations Rs m4696,400 7.3%  
From Investments Rs m29-4,985 -0.6%  
From Financial Activity Rs m-464-1,775 26.1%  
Net Cashflow Rs m35-473 -7.3%  

Share Holding

Indian Promoters % 32.9 40.4 81.3%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 0.2 8.4 2.1%  
FIIs % 0.6 10.7 5.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 19.9 333.7%  
Shareholders   20,121 109,995 18.3%  
Pledged promoter(s) holding % 36.4 0.0 90,900.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  NATCO PHARMA  AJANTA PHARMA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Feb 21, 2018 03:35 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS